CEB-01 in Locally Resectable Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Pancreatic Carcinoma
Interventions
PROCEDURE

Standard surgery

The location and size of the tumor determine the type of surgery.

DRUG

CEB-01

It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.

Trial Locations (4)

28040

RECRUITING

H. Clínico San Carlos, Madrid

41013

RECRUITING

H.U. Virgen del Rocío, Seville

46010

RECRUITING

H. Clínico Univ. de Valencia, Valencia

08036

RECRUITING

Hospital Clínico y Provincial de Barcelona, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

MFAR

OTHER

lead

CEBIOTEX

INDUSTRY